Investor Relations

About

ResApp Health Limited (ASX:RAP) is developing healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease without the need for additional hardware. ResApp has been granted an exclusive license from The University of Queensland for technology that uses sound to diagnose respiratory diseases including pneumonia, bronchitis, chronic obstructive pulmonary disease and asthma. ResApp was formed to commercialise this technology by developing the world’s first clinically-tested, regulatory-approved respiratory diagnostic application for smartphones.

Headquarters

Level 8, 127 Creek St
Brisbane, QLD 4000

Registered Office

Level 24, 44 St Georges Tce
Perth, WA 6000

Board of Directors

Dr Roger Aston – Non-Executive Chairman
Dr Tony Keating – Chief Executive Officer and Managing Director
Brian Leedman – Executive Director and Vice President, Corporate Affairs
Chris Ntoumenopoulos – Non-Executive Director

Listing

Australian Securities Exchange
ASX code: RAP

Share price

Please refer to the ASX website for current share price and history.

Share Registry

Link Market Services Limited
Level 12 QV1 Building
250 St Georges Terrace
Perth WA 6000

Investor Relations Contact

Brian Leedman
Executive Director and VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au